Follow up of Intravesical N-803 Plus BCG in BCG-Naive Non-Muscle Invasive Bladder Cancer (NMIBC)
← catalyst calendarNCT05981131 · readout in 2,568 d
Sponsored by ImmunityBio, Inc. (industry) · IBRX — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
6actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-08-17 | actual | When the study began enrolling |
| Primary completion | 2033-08-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2033-08-30 | estimated | The whole study's end, after follow-up |
| First posted | 2023-08-08 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-29 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Non Muscle Invasive Bladder Cancer
Intervention
- Drug: N803 plus Bacillus Calmette-Guerin (BCG)
Primary outcomes
what the primary-completion date above is the date OFObtain Long Term Follow-Up data to be summarized using descriptive statistics
measured assessed up to 60 months
Assess the Complete response yearly
measured assessed up to 60 months
Asses Disease-free Survival
measured assessed up to 60 months
Permalink · IBRX's whole pipeline · Catalyst calendar · Every registered study · What changed